Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumo...

Full description

Saved in:
Bibliographic Details
Published inCancer research and treatment Vol. 54; no. 1; pp. 1 - 9
Main Authors Yoon, Shinkyo, Kim, Miso, Hong, Yong Sang, Kim, Han Sang, Kim, Seung Tae, Kim, Jihun, Yun, Hongseok, Yoo, Changhoon, Ahn, Hee Kyung, Kim, Hyo Song, Lee, In Hee, Kim, In-Ho, Park, Inkeun, Jeong, Jae Ho, Cheon, Jaekyung, Kim, Jin Won, Yun, Jina, Lim, Sun Min, Cha, Yongjun, Jang, Se Jin, Zang, Dae Young, Kim, Tae Won, Kang, Jin Hyoung, Kim, Jee Hyun
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Cancer Association 01.01.2022
대한암학회
Subjects
High-Throughput Nucleotide Sequencing - methods
High-Throughput Nucleotide Sequencing - standards
Humans
Medical Oncology - standards
Neoplasms - diagnosis
Neoplasms - genetics
Neoplasms - therapy
Practice Guidelines as Topic
Precision Medicine - methods
Republic of Korea
Societies, Medical
Special
의학일반
Republic of Korea
Advanced solid cancer
Genomic alterations
Next-generation sequencing
Molecular tumor board
Precision Medicine
Online AccessGet full text
ISSN1598-2998
2005-9256
2005-9256
DOI10.4143/crt.2021.1115

Cover

Abstract Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea’s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.
AbstractList Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea's public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion. KCI Citation Count: 0
Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea's public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.
Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea's public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea's public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.
Author Lee, In Hee
Yun, Jina
Jeong, Jae Ho
Kim, Han Sang
Hong, Yong Sang
Kim, Miso
Jang, Se Jin
Yoo, Changhoon
Ahn, Hee Kyung
Park, Inkeun
Kim, Hyo Song
Cha, Yongjun
Yoon, Shinkyo
Kang, Jin Hyoung
Kim, In-Ho
Zang, Dae Young
Kim, Jihun
Lim, Sun Min
Kim, Seung Tae
Yun, Hongseok
Kim, Jee Hyun
Kim, Jin Won
Kim, Tae Won
Cheon, Jaekyung
AuthorAffiliation 5 Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
4 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
11 Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
3 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
10 Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
12 Division of Medical Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
14 Department of Internal Medicine, Hallym University Medical Center, Hallym University, Anyang, Korea
1 De
AuthorAffiliation_xml – name: 8 Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, Daegu, Korea
– name: 13 Center for Colorectal Cancer, National Cancer Center, Research Institute and Hospital, Goyang, Korea
– name: 6 Department of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
– name: 10 Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
– name: 14 Department of Internal Medicine, Hallym University Medical Center, Hallym University, Anyang, Korea
– name: 3 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
– name: 5 Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
– name: 9 Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
– name: 4 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
– name: 12 Division of Medical Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
– name: 1 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
– name: 7 Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea
– name: 11 Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
– name: 2 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
Author_xml – sequence: 1
  givenname: Shinkyo
  surname: Yoon
  fullname: Yoon, Shinkyo
– sequence: 2
  givenname: Miso
  surname: Kim
  fullname: Kim, Miso
– sequence: 3
  givenname: Yong Sang
  surname: Hong
  fullname: Hong, Yong Sang
– sequence: 4
  givenname: Han Sang
  surname: Kim
  fullname: Kim, Han Sang
– sequence: 5
  givenname: Seung Tae
  surname: Kim
  fullname: Kim, Seung Tae
– sequence: 6
  givenname: Jihun
  surname: Kim
  fullname: Kim, Jihun
– sequence: 7
  givenname: Hongseok
  surname: Yun
  fullname: Yun, Hongseok
– sequence: 8
  givenname: Changhoon
  surname: Yoo
  fullname: Yoo, Changhoon
– sequence: 9
  givenname: Hee Kyung
  surname: Ahn
  fullname: Ahn, Hee Kyung
– sequence: 10
  givenname: Hyo Song
  surname: Kim
  fullname: Kim, Hyo Song
– sequence: 11
  givenname: In Hee
  surname: Lee
  fullname: Lee, In Hee
– sequence: 12
  givenname: In-Ho
  surname: Kim
  fullname: Kim, In-Ho
– sequence: 13
  givenname: Inkeun
  surname: Park
  fullname: Park, Inkeun
– sequence: 14
  givenname: Jae Ho
  surname: Jeong
  fullname: Jeong, Jae Ho
– sequence: 15
  givenname: Jaekyung
  surname: Cheon
  fullname: Cheon, Jaekyung
– sequence: 16
  givenname: Jin Won
  surname: Kim
  fullname: Kim, Jin Won
– sequence: 17
  givenname: Jina
  surname: Yun
  fullname: Yun, Jina
– sequence: 18
  givenname: Sun Min
  surname: Lim
  fullname: Lim, Sun Min
– sequence: 19
  givenname: Yongjun
  surname: Cha
  fullname: Cha, Yongjun
– sequence: 20
  givenname: Se Jin
  surname: Jang
  fullname: Jang, Se Jin
– sequence: 21
  givenname: Dae Young
  surname: Zang
  fullname: Zang, Dae Young
– sequence: 22
  givenname: Tae Won
  surname: Kim
  fullname: Kim, Tae Won
– sequence: 23
  givenname: Jin Hyoung
  surname: Kang
  fullname: Kang, Jin Hyoung
– sequence: 24
  givenname: Jee Hyun
  surname: Kim
  fullname: Kim, Jee Hyun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34902959$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002802574$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp1kktv1DAUhSNURB-wZIu8hEUGP-IkZoE0jGCo2qHVzHRteZybTpjEHmynhb_Gr8PJlAqQWN3F_c45lu85TY6MNZAkLwmeZCRjb7ULE4opmRBC-JPkhGLMU0F5fpScEC7KlApRHien3n_FOM9YQZ4lxywTmAouTpKfS9C268BUKjTWeFRbh8IW0I0HZGv0Bb6HdA4G3LhHK_jWg9GNuUXKVCO5sC3ovlUOrfsuqj9Y5arR5zpqwASP7puwRdPqThkNFZoNw71DU7SEvXUB1c526GK1uBo9L2arObp2oBs_JC6gamIexKeEe-t2Q_Tc2X7_PHlaq9bDi4d5ltx8-riefU4vr-bns-llqjNKQpoRjdkm58A2tOAYGNebvGawwYoqgXldcMU4i-ssg7LSAJqWJdngXHCd5ZSdJW8OvsbVcqcbaVUzzlsrd05Ol-tzKQQpaJlH9v2B3febDqKZCU61cu-aTrkfo_LvjWm20edOlgXPCRHR4PWDgbPxp32QXeM1tK0yYHsvaU4wLnImioi--jPrMeT3cSOQHgDtrPcO6keEYDmUR8byyKE8cihP5Nk_vG7CePb41Kb9j-oXBxvKpg
CitedBy_id crossref_primary_10_1038_s41598_024_84909_9
crossref_primary_10_4143_crt_2023_1043
crossref_primary_10_1002_ijc_34558
crossref_primary_10_4132_jptm_2023_08_26
crossref_primary_10_1016_j_esmoop_2024_103709
crossref_primary_10_4103_ejcrp_eJCRP_D_23_00050
crossref_primary_10_1200_PO_23_00166
crossref_primary_10_3904_kjm_2022_97_5_319
crossref_primary_10_4048_jbc_2022_25_e41
crossref_primary_10_4143_crt_2023_446
crossref_primary_10_1186_s12967_024_05227_2
crossref_primary_10_2220_biomedres_43_115
crossref_primary_10_4132_jptm_2023_11_01
crossref_primary_10_1186_s12885_024_12338_y
Cites_doi 10.1016/j.jmoldx.2016.09.006
10.1158/1078-0432.ccr-20-3054
10.1200/po.17.00011
10.1200/po.20.00495
10.1016/s0140-6736(16)00004-0
10.1038/s41571-020-00457-x
10.1111/joim.12429
10.1038/s41467-020-18613-3
10.1186/s40425-019-0647-4
10.1200/cci.18.00001
10.1093/annonc/mdz116
10.4143/crt.2018.132
10.1186/s12920-021-00909-y
10.1016/j.trecan.2020.05.008
10.1038/s41431-017-0081-3
10.1016/j.ccell.2014.12.001
10.1093/annonc/mdx528
10.2196/26220
10.1038/s41598-021-91974-x
10.1111/cas.15132
10.1093/annonc/mdy263
10.1093/jamiaopen/ooz045
10.1056/nejmp1500523
10.1016/j.ejca.2017.07.019
10.1007/s40291-014-0115-2
10.5858/arpa.2018-0172-oa
10.4143/crt.2021.218
10.4143/crt.2020.559
10.1038/nature15819
10.18632/oncotarget.17199
10.1016/s1470-2045(20)30445-9
10.1186/s12967-019-2039-4
10.1200/cci.19.00169
10.5858/arpa.2015-0261-sa
ContentType Journal Article
Copyright Copyright © 2022 by the Korean Cancer Association 2022
Copyright_xml – notice: Copyright © 2022 by the Korean Cancer Association 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.4143/crt.2021.1115
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-9256
EndPage 9
ExternalDocumentID oai_kci_go_kr_ARTI_9917286
PMC8756119
34902959
10_4143_crt_2021_1115
Genre Journal Article
GeographicLocations Republic of Korea
GeographicLocations_xml – name: Republic of Korea
GrantInformation_xml – fundername: Ministry of Health and Welfare
  grantid: 1720150
GroupedDBID ---
29B
5-W
53G
8JR
9ZL
AAYXX
ABDBF
ACUHS
ACYCR
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
F5P
HYE
OK1
RPM
TR2
C1A
CGR
CUY
CVF
ECM
EIF
M~E
NPM
7X8
5PM
ID FETCH-LOGICAL-c421t-41c03b65e3b2750e35cb6f3eb0a2a905f75a353e3b44e8dceec2881b0695c4623
ISSN 1598-2998
2005-9256
IngestDate Sun Mar 09 07:52:45 EDT 2025
Thu Aug 21 14:01:55 EDT 2025
Thu Jul 10 23:04:53 EDT 2025
Thu Jan 02 22:52:41 EST 2025
Tue Jul 01 03:18:51 EDT 2025
Thu Apr 24 23:10:58 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Advanced solid cancer
Genomic alterations
Next-generation sequencing
Molecular tumor board
Precision Medicine
Language English
License This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c421t-41c03b65e3b2750e35cb6f3eb0a2a905f75a353e3b44e8dceec2881b0695c4623
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8756119
PMID 34902959
PQID 2610076397
PQPubID 23479
PageCount 9
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9917286
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8756119
proquest_miscellaneous_2610076397
pubmed_primary_34902959
crossref_primary_10_4143_crt_2021_1115
crossref_citationtrail_10_4143_crt_2021_1115
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-01-01
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – month: 01
  year: 2022
  text: 2022-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Cancer research and treatment
PublicationTitleAlternate Cancer Res Treat
PublicationYear 2022
Publisher Korean Cancer Association
대한암학회
Publisher_xml – name: Korean Cancer Association
– name: 대한암학회
References ref13
ref35
ref12
ref34
ref15
ref37
ref14
ref36
ref31
ref30
ref11
ref10
ref2
ref1
Le (ref23) 2017
ref17
ref39
ref16
ref38
ref19
Le (ref24) 2015
ref26
ref25
ref20
ref22
ref21
Zehir (ref3) 2017
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref6
ref5
Jennings (ref18) 2017
ref40
(ref33) 2020
(ref32) 2018
37114287 - Cancer Res Treat. 2023 Apr 21
References_xml – ident: ref14
  doi: 10.1016/j.jmoldx.2016.09.006
– ident: ref20
  doi: 10.1158/1078-0432.ccr-20-3054
– ident: ref17
  doi: 10.1200/po.17.00011
– ident: ref29
  doi: 10.1200/po.20.00495
– ident: ref39
  doi: 10.1016/s0140-6736(16)00004-0
– ident: ref15
  doi: 10.1038/s41571-020-00457-x
– ident: ref5
  doi: 10.1111/joim.12429
– start-page: 409
  volume-title: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
  year: 2017
  ident: ref23
– ident: ref36
  doi: 10.1038/s41467-020-18613-3
– ident: ref22
  doi: 10.1186/s40425-019-0647-4
– ident: ref34
  doi: 10.1200/cci.18.00001
– ident: ref25
  doi: 10.1093/annonc/mdz116
– ident: ref6
  doi: 10.4143/crt.2018.132
– ident: ref19
  doi: 10.1186/s12920-021-00909-y
– year: 2020
  ident: ref33
– start-page: 2509
  volume-title: PD-1 blockade in tumors with mismatch-repair deficiency
  year: 2015
  ident: ref24
– ident: ref27
  doi: 10.1016/j.trecan.2020.05.008
– ident: ref4
  doi: 10.1038/s41431-017-0081-3
– ident: ref10
  doi: 10.1016/j.ccell.2014.12.001
– year: 2018
  ident: ref32
– ident: ref28
  doi: 10.1093/annonc/mdx528
– ident: ref35
  doi: 10.2196/26220
– start-page: 703
  volume-title: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
  year: 2017
  ident: ref3
– ident: ref26
  doi: 10.1038/s41598-021-91974-x
– ident: ref38
  doi: 10.1111/cas.15132
– ident: ref16
  doi: 10.1093/annonc/mdy263
– ident: ref30
  doi: 10.1093/jamiaopen/ooz045
– ident: ref1
  doi: 10.1056/nejmp1500523
– ident: ref7
  doi: 10.1016/j.ejca.2017.07.019
– ident: ref13
  doi: 10.1007/s40291-014-0115-2
– ident: ref12
  doi: 10.5858/arpa.2018-0172-oa
– ident: ref37
  doi: 10.4143/crt.2021.218
– ident: ref40
  doi: 10.4143/crt.2020.559
– ident: ref2
  doi: 10.1038/nature15819
– ident: ref11
  doi: 10.18632/oncotarget.17199
– ident: ref21
  doi: 10.1016/s1470-2045(20)30445-9
– ident: ref8
  doi: 10.1186/s12967-019-2039-4
– start-page: 341
  volume-title: Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists
  year: 2017
  ident: ref18
– ident: ref31
  doi: 10.1200/cci.19.00169
– ident: ref9
  doi: 10.5858/arpa.2015-0261-sa
– reference: 37114287 - Cancer Res Treat. 2023 Apr 21;:
SSID ssj0064371
Score 2.3092613
Snippet Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1
SubjectTerms High-Throughput Nucleotide Sequencing - methods
High-Throughput Nucleotide Sequencing - standards
Humans
Medical Oncology - standards
Neoplasms - diagnosis
Neoplasms - genetics
Neoplasms - therapy
Practice Guidelines as Topic
Precision Medicine - methods
Republic of Korea
Societies, Medical
Special
의학일반
Title Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
URI https://www.ncbi.nlm.nih.gov/pubmed/34902959
https://www.proquest.com/docview/2610076397
https://pubmed.ncbi.nlm.nih.gov/PMC8756119
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002802574
Volume 54
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Cancer Research and Treatment, 2022, 54(1), , pp.1-9
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELa6uxLignhTXjIIcVkCqWMnDbe2bCnstovUVuqerDwctlqaoD4O8L-48OuYiZ2kqYq0cEkqxx2nnS_jGeebMSGvYvBRcVq23IQnFk-CthUkbmjFnDNbxaEKbUxOHo7cwZR_nolZo_Fri7W0WYdvo59780r-R6vQBnrFLNl_0GwpFBrgM-gXjqBhOF5Lxxg7LhbK7Iu0KimDU71AP8KoVteVNnYhp00XaYnYc1jsjns82Szg290MlxVQzhddcNVkv3UKqkAPT0udz66dd52hcjoenudST3vjj0js0Fv36BdB6MmONN-8vt5VlUgAocem8JDOtSsZ8JVd0gSB8SWEzz-yijygF3Xnq7JpYGjGF7iP0jgwc3PVd4A2rWg2Kx6Mba145IYxr57qM2FKaO9pM5Zdl6euIVib6da-yYOD6wgaj5ZIsWUtnExENUsWzIDRuexPz87k5GQ2OSBHzPOQHXDU6X7o9gsXAF-GYqRf3pQu7ooDvKuJrzlDB-ky2Rfn7NJ1t_yfyW1yywQutKNReIc0VHqX3CjUe4_83gEjBRBRgBgFMNIsoTtgpBUYKag771mCkeZgpDkYczkFGCmCkRZgpBo372mHaihShCJFKOYyEYq0hCIt7pVWUKQ5FO-Taf9k0htYZmMQK-KstbZ4K7Kd0BXKCXF7AuWIKHQTB-xKwALfFoknAkc4cJlz1Yb_TUWsDfGZ7foi4uDwPyCHaZaqR4S6AWNeLJQvYsF9geF_4gS-FyeRK7hSTfKm0JCMTNV83Lzlm4ToGRUqQaESFYqxtGiS12X377pczN86vgR1y6toLrHAO56_ZvJqKSGM_SQhaPNY222SFwUaJFh9fJUXpCrbrCRzkd2EL-Wb5KFGRzmew32bwU9pEq-Gm7IDDli_ks4v88rybQ_sdst_fI1xn5Cb1bP5lByulxv1DPzzdfjcPA1_ACvp7Rw
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recommendations+for+the+Use+of+Next-Generation+Sequencing+and+the+Molecular+Tumor+Board+for+Patients+with+Advanced+Cancer%3A+A+Report+from+KSMO+and+KCSG+Precision+Medicine+Networking+Group&rft.jtitle=Cancer+research+and+treatment&rft.au=Yoon%2C+Shinkyo&rft.au=Kim%2C+Miso&rft.au=Hong%2C+Yong+Sang&rft.au=Kim%2C+Han+Sang&rft.date=2022-01-01&rft.issn=2005-9256&rft.eissn=2005-9256&rft.volume=54&rft.issue=1&rft.spage=1&rft_id=info:doi/10.4143%2Fcrt.2021.1115&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon